Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Silence Therapeutics plc (SLN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
21.63-0.54 (-2.44%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close22.17
Open22.00
Bid21.64 x 1100
Ask22.11 x 900
Day's Range21.60 - 22.00
52 Week Range20.50 - 35.00
Volume4,866
Avg. Volume43,680
Market Cap647.347M
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-1.97
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4,944.59
  • GlobeNewswire

    Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference

    Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference 5 January 2022 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a fireside chat during the H.C. Wainwright BioConnect Virtual Conferen

  • GlobeNewswire

    New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases

    New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases Data presented at 2021 ASH annual meeting showed durable reductions in serum iron and transferrin saturation, strong safety profile and long duration of action Data support ongoing studies in patients with thalassemia and myelodysplastic syndrome and a new planned study in polycythemia vera 12 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a lead

  • GlobeNewswire

    Silence Therapeutics Welcomes Deep Track Capital as New Shareholder

    1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Deep Track Capital, a U.S. investment firm focused exclusively on the life sciences industry, purchased approximately $22 million of American Depository Shares (ADSs) in Silence from existing shareholder

Advertisement
Advertisement